Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Imidazoles
  • Indazoles
  • Thyroid Neoplasms

abstract

  • Axitinib is a selective inhibitor of VEGFR with compelling antitumor activity in all histologic subtypes of advanced thyroid cancer.

publication date

  • October 10, 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4859206

Digital Object Identifier (DOI)

  • 10.1200/JCO.2007.15.9566

PubMed ID

  • 18541897

Additional Document Info

start page

  • 4708

end page

  • 13

volume

  • 26

number

  • 29